Amniotic stem cell transplantation therapy for type 2 diabetes: 3 years' follow-up report

These case series present a retrospective analysis of clinical effects that an allogeneic amniotic cell transplantation can have in treating 4 patients with type 2 diabetes.

Eligible diabetic patients were onset within 3 years, with fasting blood glucose > 7.0 mmol/l. Stem - cells that are collected from neonatal amniotic membrane when a child is born (2 x 107 cells) - are used for the treatment of these patients. Measured by the flow cytometry, stem cells transfer clusters of differentiation CD113 and CD34 at a high level, and through the femoral artery on the left, they are administered into the patient's pancreatic dorsal artery.

The major outcome of the study is the improvement of glycemic control. After withdrawing insulin completely, 13.2 months later, there is a reincrease in the level of blood glucose of the patient. After adjusting their treatment again, no one required using insulin again; only need metformin (250-500 mg/day) to control blood glucose levels.

Since this therapy showed no effects on C-peptide, our results suggested one plausible therapeutic strategy improving glycemic control by increasing insulin sensitivity.